Muscle mass loss is associated with physical dysfunction in patients with early rheumatoid arthritis

Jie Pan, Yao-Wei Zou, Yingying Zhu, Jian‐Zi Lin, Tao Wu, Zehong Yang, Xuepei Zhang, Qian Zhang, Hu-Wei Zheng, Xiaoling He, Wan‐Mei Cheng, Jian‐Da Ma, Lie DaiFrontiers in Nutrition 2022 · DOI

Abstract

Our data indicate the importance of early detection of muscle involvement in the early stage of RA and imply the significance of early aggressive control of disease activity for the prevention of myopenia and physical dysfunction in patients with early RA. Our study provides a new perspective on RA management.

Introduction

Rheumatoid arthritis (RA) is a systemic inflammatory disease traditionally characterized by progressive joint destruction. However, it frequently leads to "rheumatoid cachexia," a condition where patients lose muscle mass while maintaining or increasing fat mass. While well-documented in chronic, long-standing RA, the prevalence and impact of muscle loss—specifically myopenia—in the very early stages of the disease (within 12 months of onset) have remained poorly understood.

This study addresses this gap by investigating whether muscle wasting is a primary driver of physical dysfunction at the disease's onset. Identifying the timing of muscle loss is critical for clinical management; if it occurs early, the window for intervention to prevent long-term disability is much narrower than previously assumed.

Methods

The researchers conducted a large-scale cross-sectional study using a Chinese RA cohort recruited between 2015 and 2022. The study included 1,008 RA patients, categorized into early RA (n=190, duration ≤ 12 months) and established RA (n=818, duration > 12 months), compared against 2,017 healthy controls.

Flow diagram of patient recruitment and classification into early and established RA groups.

Body composition was measured via Bioelectric Impedance Analysis (BIA). Myopenia was defined using the Appendicular Skeletal Muscle Mass Index (ASMI) thresholds (≤ 7.0 kg/m² for men and ≤ 5.7 kg/m² for women). Physical function was assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). To ensure fair comparison, Propensity Score Matching (PSM) was used to balance age and gender across groups, and multivariate logistic regression isolated the independent effects of disease activity on muscle loss.

Results

Prevalence of Myopenia

A key finding was that muscle loss is not a late-stage complication. The prevalence of myopenia in early RA (41.3%) was statistically indistinguishable from that in established RA (50.4%), yet significantly higher than the 15.8% found in healthy controls ($P < 0.0167$). This suggests that the biological processes driving muscle atrophy are highly active from the moment the disease manifests.

High disease activity was a primary predictor of muscle loss. Multivariate analysis showed that for every unit increase in the DAS28-CRP score, the odds of having myopenia increased significantly (Adjusted Odds Ratio [AOR] 1.558). This supports the theory that systemic pro-inflammatory cytokines, such as TNF-α and IL-6, directly suppress muscle cell differentiation and induce atrophy.

Logistic regression analysis of factors associated with myopenia in early and established RA, highlighting the impact of disease activity scores.

Functional Impact

In early RA patients, myopenia was specifically associated with difficulties in walking and performing daily activities. Patients with myopenia were nearly three times more likely to suffer from physical dysfunction than those with normal muscle mass (AOR 2.983). Interestingly, the early RA group exhibited higher disease activity and physical dysfunction scores than the established RA group, likely due to the latter's long-term pharmacological management.

Discussion and Conclusion

This study demonstrates that myopenia is remarkably prevalent in early RA and is independently linked to physical disability. The findings suggest that muscle loss is a functional "double whammy" alongside joint pain, occurring much earlier than previously thought.

While the cross-sectional nature of the study limits definitive causal conclusions, the biological plausibility of inflammation-driven muscle wasting is strong. Future management of RA should prioritize early, aggressive "treat-to-target" strategies to control inflammation, potentially combined with nutritional interventions (e.g., leucine supplementation) and resistance training to prevent or reverse early-onset muscle loss. Early detection of muscle involvement is essential to preserving physical function in RA patients.

Summary updated

Abstract

Our data indicate the importance of early detection of muscle involvement in the early stage of RA and imply the significance of early aggressive control of disease activity for the prevention of myopenia and physical dysfunction in patients with early RA. Our study provides a new perspective on RA management.
BibTeX
@inproceedings{pan2022muscle,
  author = {Jie Pan and Yao-Wei Zou and Yingying Zhu and Jian‐Zi Lin and Tao Wu and Zehong Yang and Xuepei Zhang and Qian Zhang and Hu-Wei Zheng and Xiaoling He and Wan‐Mei Cheng and Jian‐Da Ma and Lie Dai},
  title = {{Muscle mass loss is associated with physical dysfunction in patients with early rheumatoid arthritis}},
  booktitle = {Frontiers in Nutrition},
  year = {2022},
  doi = {10.3389/fnut.2022.1007184},
}
Figure